David A. Lewin, Ph.D., has over fifteen years of business development, licensing, and marketing experience in life sciences at Yale Ventures.  He has spent well over 20 years successfully managing scientifically-based business alliances with biotech and pharmaceutical leaders in the U.S., Europe and Asia. He has scientific business expertise in pharmaceuticals, biomarkers, cell biology, genomics and proteomics and in many disease areas.  Dave has been instrumental in establishing Yale ventures, including Kolltan Pharmaceuticals (acquired by Celldex; CLDX), Biohaven Pharmaceuticals (BHVN), Inozyme Pharma (INZY), and Kleo Pharmaceuticals. Prior to his work at OCR, Dave was a group leader for CuraGen Corporation in Collaborative Research/Alliance Management and Biomarkers Discovery and Development.

Dave holds a B.A. in Biochemistry and Cell Biology from the University of California San Diego and a Ph.D. in Cell Biology from Yale (Mellman Lab).